Biodexa Pharmaceuticals PLC (BDRX) has announced the immediate appointment of Gary Shangold as their new Chief Medical Officer. Prior to joining Biodexa, Shangold served as Chief Medical Officer at Enteris BioPharma, a fully-owned subsidiary of SWK Holdings Corporation.
Stephen Stamp, the CEO and CFO of Biodexa, stated, "As Biodexa progresses into the advanced clinical phases, including a forthcoming global Phase 3 registrational study for FAP, it is crucial that we engage experts with Gary's extensive knowledge and experience. Having previously collaborated with Gary at Xanodyne, where his contributions were pivotal in obtaining two NDAs, I am confident in the value he will bring to Biodexa."
